Skip to content

OS Therapies OSTX Operating Income

Operating Income at other companies

Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
CTO
Citius Oncology, Inc.CTOR
-$28.61M-283%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$20.9M-42.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$69.79M-8.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%

Segments

By segment

See full
Chief Operating Decision Maker-$10.17M-103%

Other financials

Income statement

See full
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's operating income?
OS Therapies (OSTX) reported operating income of -$10.17M in Q1 2026.
How has OS Therapies's operating income changed year-over-year?
OS Therapies's operating income decreased by 103.4% year-over-year, from -$5M to -$10.17M.
What is the long-term trend for OS Therapies's operating income?
Over 2 years (2023 to 2025), OS Therapies's operating income has grown at a 157.1% compound annual growth rate (CAGR), from -$4.34M to -$28.71M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.